

#### ESMO Preceptorship Programme

Non small cell Lung carcinoma – Danemark – 7/8 July



### Optimal management of IIIAN2 NSCLC




# Clinical case presentation

- Male. 67 years old. No history of smoking
- August 2012: Nocturnal <u>dry cough refractory to</u> <u>symptomatic treatment</u>, without pain, hemoptysis, or dyspnea.
- Chest Ray: Right basal opacity.



• CT scan of the chest: bronchopulmonary tumor in the lower right lobe measuring 60 mm. Absence of parenchymal lung nodules or mediastinal lymphadenopathy.






• Bronchoscopy: complete stenosis of the basal pyramid in the right bronchial tree.

• **Biopsy:** well-differentiated squamous cell lung cancer.

 Ct scan of Brain and abdomen and Bone scan: No evidence of distant lesions.



• PET CT scan: Large excavated mass measuring 61 mm (SUV = 23) and ADP of Barety loge (SUV = 8.3).







- The patient underwent <u>mediastinoscopy</u> with biopsy of the lymph node of the Barety loge:
- Histology: lymph node metastasis of well-differentiated squamous cell carcinoma without capsular rupture





#### First question: How to treat?

- 1. surgery alone
- 2. exclusive concomittent chemoradiotherapy
- 3. Neoadjuvant chemotherapy followed by surgery
- 4. Neoadjuvant chemo-radiotherapy followed by

surgery



 The patient received neoadjuvant chemotherapy (3 cycles of paclitaxel-carboplatin) with good tolerance.

Evaluation objectived a ganglionnar downstaiging.

 He underwent then lobectomy with lymph node dissection.

 Anatomopathology: squamous carcinoma well differentiated, measuring 5cm, limits of resection free of tumor, 12 N - / 12N => ypT2N0M0.



### Second question: Would you

Follow up?

Treat with adjuvant chemotherapy?



 The patient is followed up every 3 months with no evidence of relapse.

## Take home messages

- Stage IIIA N2: heterogenous subgroup.
- Combined modality approach is recommended if the patient is a candidate for treatment with curative intent.
- Induction chemotherapy or RT CT should be considered as the initial treatment for selected patients with clinically evident N2 in potentially resectable disease followed by a locoregional intervention.



### Thank you

